Artificial airway auxiliary establishment method and related products

Abstract

An embodiment of the present application provides an auxiliary method for establishing an artificial airway and related products. The method receives drug selection information, the drug selection information is used to determine the drug, obtains a drug metabolism model corresponding to the drug, the drug metabolism model is used to indicate the relationship between the concentration and time of the drug in a target area of ​​the human body, obtains a first configuration parameter of the drug, the first configuration parameter includes a first target concentration, and calculates the time required for the concentration of the drug to reach the first target concentration in the target area according to the first configuration parameter and the drug metabolism model to obtain a first time; the success rate of establishing an artificial airway can be improved.

Description

Technical Field

[0001] The present application relates to the field of medical technology, and in particular to a method for assisting in establishing an artificial airway and related products. Background Art

[0002] During the clinical treatment of critically ill patients, patients may experience difficulty breathing. In order to keep the patient's airway open and ensure normal respiratory function, doctors usually need to establish an artificial airway for the patient to assist ventilation. Determining the appropriate time to establish an artificial airway is the basis for successfully establishing an artificial airway.

[0003] In current clinical applications, doctors need to inject relevant anesthetic drugs into patients before establishing an artificial airway. Doctors then judge whether the patient's body is suitable for establishing an artificial airway based on the patient's body characteristics, thereby determining the timing of establishing an artificial airway.

[0004] However, this method relies entirely on the doctor's subjective judgment and is overly dependent on the doctor's mastery of anesthetic drugs and operating experience. The timing of establishing an artificial airway is not accurately judged, and the patient may not be in a state suitable for establishing an artificial airway, resulting in a low success rate in establishing an artificial airway. Summary of the invention

[0005] The embodiments of the present application disclose a method for assisting in establishing an artificial airway and related products, which can improve the success rate of establishing an artificial airway.

[0006] In a first aspect, an embodiment of the present application discloses a method for assisting in establishing an artificial airway, the method comprising:

[0007] receiving drug selection information, wherein the drug selection information is used to determine the drug;

[0008] Obtaining a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used to indicate the relationship between the concentration and time of the drug in a target area of ​​a human body;

[0009] Acquire a first configuration parameter of the drug, wherein the first configuration parameter includes a first target concentration;

[0010] According to the first configuration parameter and the drug metabolism model, the time required for the concentration of the drug to reach the first target concentration in the target area is calculated to obtain a first time.

[0011] In a possible implementation manner of the first aspect, the first configuration parameter further includes a target control method, and the target control method includes plasma target control or effect chamber target control;

[0012] When the target control method is the plasma target control, the target area is the plasma;

[0013] When the above-mentioned target control method is the above-mentioned effect chamber target control, the above-mentioned target area is the effect chamber.

[0014] In a possible implementation of the first aspect,

[0015] The first configuration parameter also includes a target control method, and the target control method includes plasma target control and effect chamber target control;

[0016] The target area is the plasma and the effect chamber, and the first target concentration includes a first target plasma concentration and a first target effect chamber concentration;

[0017] The step of calculating the time required for the concentration of the drug to reach the first target concentration in the target area according to the first configuration parameter and the drug metabolism model to obtain the first time includes:

[0018] According to the first configuration parameter and the drug metabolism model, the time required for the concentration of the drug in the plasma to reach the first target plasma concentration is calculated to obtain the first time;

[0019] Alternatively, the time required for the concentration of the drug in the effect chamber to reach the first target effect chamber concentration is calculated to obtain the first time;

[0020] Alternatively, the time required for the concentration of the drug in the plasma and the effect chamber to reach the first target plasma concentration and the first target effect chamber concentration is calculated to obtain the first time.

[0021] In a possible implementation of the first aspect, the first configuration parameter further includes a first ratio concentration and a first infusion rate;

[0022] Before obtaining the first configuration parameter of the drug, the method further includes:

[0023] Obtain patient status information;

[0024] According to the state information, the first ratio concentration and the first infusion rate are determined.

[0025] In a possible implementation manner of the first aspect, the method further includes:

[0026] According to the first configuration parameter and the drug metabolism model, the relationship between the concentration of the drug and time in the target area is calculated from the start of the drug injection, and the relationship is displayed on a display.

[0027] In a possible implementation manner of the first aspect, the method further includes:

[0028] receiving configuration parameter change information of the above-mentioned drug;

[0029] According to the configuration parameter change information, modify the first configuration parameter to obtain the second configuration parameter, wherein the second configuration parameter includes a second target concentration;

[0030] The time required for the concentration of the drug to reach the second target concentration in the target area is calculated according to the second configuration parameter and the drug metabolism model to obtain a second time.

[0031] In a possible implementation manner of the first aspect, before receiving the configuration parameter change information of the drug, the method further includes:

[0032] Acquiring status change information of the patient, where the status change information is used to indicate a sudden change in the patient's physical status;

[0033] The configuration parameter change information is determined based on the status change information.

[0034] In a second aspect, an embodiment of the present application discloses an auxiliary device for establishing an artificial airway, the device comprising:

[0035] A receiving unit, used for receiving drug selection information, wherein the drug selection information is used for determining a drug;

[0036] An acquisition unit, used for acquiring a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used for indicating the relationship between the concentration and time of the drug in the target area of ​​the human body;

[0037] The acquisition unit is further used to acquire a first configuration parameter of the drug, wherein the first configuration parameter includes a first target concentration;

[0038] The calculation unit is used to calculate the time required for the concentration of the drug to reach the first target concentration in the target area according to the first configuration parameter and the drug metabolism model to obtain a first time.

[0039] In a possible implementation manner of the second aspect, the first configuration parameter further includes a target control method, and the target control method includes plasma target control or effect chamber target control;

[0040] When the target control method is the plasma target control, the target area is the plasma;

[0041] When the above-mentioned target control method is the above-mentioned effect chamber target control, the above-mentioned target area is the effect chamber.

[0042] In a possible implementation manner of the second aspect, the first configuration parameter further includes a target control mode, and the target control mode includes plasma target control and effect chamber target control;

[0043] The target area is the plasma and the effect chamber, and the first target concentration includes a first target plasma concentration and a first target effect chamber concentration;

[0044] The calculation unit is specifically used to calculate the time required for the concentration of the drug in the plasma to reach the first target plasma concentration according to the first configuration parameter and the drug metabolism model, so as to obtain the first time;

[0045] Alternatively, the calculation unit is specifically used to calculate the time required for the concentration of the drug in the effect chamber to reach the first target effect chamber concentration, to obtain the first time;

[0046] Alternatively, the calculation unit is specifically used to calculate the time required for the concentration of the drug in the plasma and the effect chamber to reach the first target plasma concentration and the first target effect chamber concentration to obtain the first time.

[0047] In a possible implementation of the second aspect, the first configuration parameter further includes a first ratio concentration and a first infusion rate;

[0048] The acquisition unit is also used to acquire the patient's status information;

[0049] The above device also includes:

[0050] A determination unit is used to determine the first ratio concentration and the first infusion rate according to the state information.

[0051] In a possible implementation manner of the second aspect, the calculation unit is further used to calculate, based on the first configuration parameter and the drug metabolism model, a change relationship between the concentration of the drug in the target area and time from the start of the drug injection;

[0052] The above device also includes:

[0053] The display unit is used to display the above-mentioned change relationship on a display.

[0054] In a possible implementation manner of the second aspect, the receiving unit is further used to receive configuration parameter change information of the drug;

[0055] The calculation unit is used to calculate the time required for the concentration of the drug to reach a second target concentration in the target area according to the second configuration parameter and the drug metabolism model, so as to obtain the second time.

[0056] The above device also includes:

[0057] The modification unit is used to modify the first configuration parameter according to the configuration parameter change information to obtain the second configuration parameter, wherein the second configuration parameter includes the second target concentration.

[0058] In a possible implementation manner of the second aspect, the acquisition unit is further used to acquire state change information of the patient, where the state change information is used to indicate a sudden change in the physical state of the patient;

[0059] The above-mentioned determination unit is further used to determine the above-mentioned configuration parameter change information according to the above-mentioned state change information.

[0060] In a third aspect, an embodiment of the present application provides an electronic device, comprising: a memory for storing programs; a processor for executing the programs stored in the memory, and when the programs are executed, the processor is used to execute the method of the first aspect and any optional implementation method.

[0061] In a fourth aspect, an embodiment of the present application provides a computer-readable storage medium, wherein the computer storage medium stores a computer program, wherein the computer program includes program instructions, and when the program instructions are executed by a processor, the processor executes a method as described in the first aspect and any one of the optional implementations.

[0062] In a fifth aspect, an embodiment of the present application provides a computer program product, which includes: instructions or computer programs; when the instructions or the computer programs are executed, the method in any possible implementation manner in the first aspect is implemented.

[0063] The auxiliary method for establishing an artificial airway in the embodiment of the present application receives drug selection information, the drug selection information is used to determine the drug; obtains the drug metabolism model corresponding to the drug, the drug metabolism model is used to indicate the relationship between the concentration and time of the drug in the target area of ​​the human body; obtains the first configuration parameter of the drug, the first configuration parameter includes the first target concentration; according to the first configuration parameter and the drug metabolism model, calculates the time required for the concentration of the drug to reach the first target concentration in the target area to obtain the first time. In the embodiment of the present application, the corresponding drug metabolism model can be obtained according to the drug, and the time required for the concentration of the drug in the target area to reach the target concentration can be obtained according to the configuration parameters corresponding to the drug and the drug metabolism model, so that the onset time of the drug can be predicted more accurately. At this onset time, the patient's body will be in a state suitable for establishing an artificial airway, and the appropriate time to establish an artificial airway for the patient can be objectively determined, thereby improving the success rate of establishing an artificial airway. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the background technology, the following is a brief introduction to the drawings required for use in the embodiments of the present application or the background technology.

[0065] Figure 1 A flowchart of a method for assisting in establishing an artificial airway provided in an embodiment of the present application;

[0066] Figure 2 A flowchart of another method for assisting in establishing an artificial airway provided in an embodiment of the present application;

[0067] Figure 3 A graph showing the relationship between the concentration and time of a drug provided in an embodiment of the present application;

[0068] Figure 4 A graph showing the relationship between the concentration and time of another drug provided in an embodiment of the present application;

[0069] Figure 5 A schematic diagram of the structure of an auxiliary device for establishing an artificial airway provided in an embodiment of the present application;

[0070] Figure 6 A schematic diagram of the structure of an electronic device provided in an embodiment of the present application. DETAILED DESCRIPTION

[0071] In order to make the objectives, technical solutions and advantages of the present application clearer, the present application will be further described below in conjunction with the accompanying drawings.

[0072] The terms "first" and "second" in the specification, claims and drawings of this application are only used to distinguish different objects, rather than to describe a specific order. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, system, product or device that includes a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units that are not listed, or may optionally include other steps or units that are inherent to these processes, methods, products or devices.

[0073] The "embodiment" mentioned in this article means that the specific features, structures or characteristics described in conjunction with the embodiment can be included in at least one embodiment of the present application. The appearance of this phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It can be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.

[0074] In the present application, "at least one (item)" means one or more, "more than one" means two or more, "at least two (items)" means two or three and more than three, and "and / or" is used to describe the association relationship of associated objects, indicating that three relationships may exist. For example, "A and / or B" can mean: only A exists, only B exists, and A and B exist at the same time, where A and B can be singular or plural. The character " / " generally indicates that the previous and next associated objects are in an "or" relationship. "At least one of the following" or similar expressions refers to any combination of these items. For example, at least one of a, b or c can mean: a, b, c, "a and b", "a and c", "b and c", or "a and b and c".

[0075] The embodiments of the present invention provide an auxiliary method for establishing an artificial airway and related products. In order to more clearly describe the scheme of the present invention, some knowledge related to the auxiliary method for establishing an artificial airway and related products provided in the embodiments of the present application is first introduced below.

[0076] Artificial airway: An artificial airway is a gas passage established by inserting a catheter into the patient's trachea through the upper respiratory tract or directly into the patient's trachea. It can ensure the patient's airway is unobstructed and establish an effective connection between the physiological airway and the air or other gas sources, providing conditions for effective drainage, unobstructed airway, mechanical ventilation, and treatment of lung diseases. The most common artificial airway is oral or nasal endotracheal intubation, which requires the patient to maintain adequate sedation and sufficient muscle relaxation, otherwise, the intubation is likely to fail, and multiple intubations may have a certain impact on the patient's body.

[0077] Drug metabolism model: abbreviated as pharmacokinetic model, mainly quantitatively studies the process of drugs in the body, such as absorption, distribution, metabolism and excretion, and uses mathematical principles and methods to explain the dynamic laws of drugs in the body. It is the basis for determining the dosage and interval of the drug, and is used to determine whether the drug can reach a safe and effective concentration at its site of action. The concentration of the drug at the site of action changes dynamically due to the influence of the drug's in vivo process.

[0078] During the clinical treatment of critically ill patients, patients may experience difficulty breathing. In order to keep the patient's airway open and ensure normal respiratory function, doctors usually need to establish an artificial airway for the patient to assist ventilation. Determining the appropriate time to establish an artificial airway is the basis for successfully establishing an artificial airway.

[0079] In current clinical applications, doctors need to inject relevant anesthetic drugs into patients before establishing an artificial airway. Doctors then judge whether the patient's body is suitable for establishing an artificial airway based on the patient's body characteristics, thereby determining the timing of establishing an artificial airway.

[0080] However, this method relies entirely on the doctor's subjective judgment and is overly dependent on the doctor's mastery of anesthetic drugs and operating experience. The timing of establishing an artificial airway is not accurately judged, and the patient may not be in a state suitable for establishing an artificial airway, resulting in a low success rate in establishing an artificial airway.

[0081] In view of the defects of the above method, the present application embodiment provides an auxiliary method for establishing an artificial airway, such as Figure 1 As shown, the method may include the following steps:

[0082] 101. Receive drug selection information, where the drug selection information is used to determine a drug.

[0083] The above drug selection information is used to determine the drugs selected by doctors for patients during clinical medical treatment. The drugs can be divided into sedatives, analgesics and muscle relaxants according to their different uses. In the process of establishing an artificial airway, these three drugs have different effects. Sedatives can be used to slightly inhibit the cerebral cortex, reduce central nervous excitability, ease excitement, eliminate restlessness, and restore the patient's calm mood; analgesics mainly act on the central or peripheral nervous system, selectively inhibit and relieve various pains, and can relieve pain caused by fear, tension and anxiety; muscle relaxants can relax the patient's muscles to facilitate intubation operations; drugs commonly used in establishing artificial airways include dexmedetomidine, propofol and rocuronium bromide.

[0084] 102. Obtain a drug metabolism model corresponding to the drug, where the drug metabolism model is used to indicate the relationship between the concentration and time of the drug in a target area of ​​a human body.

[0085] Different drugs mentioned above correspond to different drug metabolism models; the target area is the area of ​​action of the drug, including at least one of plasma and effect chamber. Optionally, the effect chamber may include multiple effect chambers of the drug. When the concentration of the drug in the target area reaches a certain level, the corresponding pharmacological effect of the drug can be exerted, such as anesthesia, sedation and analgesia; the drug metabolism model can correctly indicate the relationship between the concentration of the drug in the target area and time during the continuous administration of the drug.

[0086] 103. Obtain a first configuration parameter of the drug, where the first configuration parameter includes a first target concentration.

[0087] Before injecting the above-mentioned drug into the patient, the configuration parameters of the drug need to be configured. For patients in different conditions, the configuration parameters are also different. When the concentration of the above-mentioned drug in the above-mentioned target area reaches the above-mentioned first target concentration, the concentration of the above-mentioned drug in the patient's body reaches an effective concentration without producing toxic reactions, so that the drug's efficacy can be better exerted, which is convenient for establishing an artificial airway.

[0088] In some implementations of the present application, the first configuration parameter further includes a target control method, and the target control method includes plasma target control or effect chamber target control;

[0089] When the target control method is the plasma target control, the target area is the plasma;

[0090] When the above-mentioned target control method is the above-mentioned effect chamber target control, the above-mentioned target area is the effect chamber.

[0091] In the process of configuring the drug, the above-mentioned target control method is also included. Different target control methods are used for different types of drugs. When the above-mentioned target area is the above-mentioned plasma, the relationship between the concentration of the above-mentioned drug in the plasma and time can be calculated according to the above-mentioned drug metabolism model. When the above-mentioned target area is the above-mentioned effect chamber, the relationship between the concentration of the above-mentioned drug in the effect chamber and time can be calculated according to the above-mentioned drug metabolism model. This embodiment can be used for drugs with different target control methods and can meet more application scenarios.

[0092] In some implementations of the present application, the first configuration parameter further includes a target control method, and the target control method includes plasma target control and effect chamber target control;

[0093] The target area is the plasma and the effect chamber, and the first target concentration includes a first target plasma concentration and a first target effect chamber concentration;

[0094] The step of calculating the time required for the concentration of the drug to reach the first target concentration in the target area according to the first configuration parameter and the drug metabolism model to obtain the first time includes:

[0095] According to the first configuration parameter and the drug metabolism model, the time required for the concentration of the drug in the plasma to reach the first target plasma concentration is calculated to obtain the first time;

[0096] Alternatively, the time required for the concentration of the drug in the effect chamber to reach the first target effect chamber concentration is calculated to obtain the first time;

[0097] Alternatively, the time required for the concentration of the drug in the plasma and the effect chamber to reach the first target plasma concentration and the first target effect chamber concentration is calculated to obtain the first time.

[0098] In the case where the above-mentioned target control method includes the above-mentioned plasma target control and effect chamber target control, the above-mentioned first target concentration includes the above-mentioned first target plasma concentration and the above-mentioned first target effect chamber concentration, the first target plasma concentration indicates the target concentration of the above-mentioned drug in plasma, and the first target effect chamber indicates the target concentration of the above-mentioned drug in the effect chamber. In an embodiment of the present application, in the case where the above-mentioned target control method includes plasma target control and effect chamber target control, the time when the concentration of the above-mentioned drug reaches the above-mentioned first target plasma concentration or reaches the above-mentioned first target effect chamber concentration, or reaches the above-mentioned first target plasma concentration and reaches the above-mentioned first target effect chamber concentration can be obtained, which is suitable for different drugs according to the actual application situation, and can determine the onset time of the above-mentioned drug. The target control method for different drugs can meet more application scenarios.

[0099] In some implementations of the present application, the first configuration parameter further includes a first ratio concentration and a first infusion rate;

[0100] Before obtaining the first configuration parameter of the drug, the method further includes:

[0101] Obtain patient status information;

[0102] According to the state information, the first ratio concentration and the first infusion rate are determined.

[0103] The above-mentioned status information indicates the physical information of the above-mentioned patient. Optionally, the physical information includes other information such as height, gender, weight and age. This information will affect the setting of the above-mentioned first ratio concentration and the above-mentioned first infusion rate. The first ratio concentration represents the ratio concentration of the above-mentioned drug in the solution, and the first infusion rate represents the infusion rate of the drug during the injection of the above-mentioned drug into the patient. For different patient populations, the ratio concentration and infusion rate of the above-mentioned drug are different. According to the above-mentioned status information of the above-mentioned patient, appropriate drug configuration parameters can be customized for different patients to improve the success rate of establishing an artificial airway.

[0104] 104. According to the first configuration parameter and the drug metabolism model, calculate the time required for the concentration of the drug to reach the first target concentration in the target area to obtain a first time.

[0105] By inputting the above-mentioned first configuration parameter into the above-mentioned drug metabolism model, the time required for the concentration of the above-mentioned drug to reach the above-mentioned first target concentration can be obtained, that is, the above-mentioned first time. Starting from the start of injection of the above-mentioned drug, after the above-mentioned first time, the optimal onset time of the drug is reached, and the doctor can perform intubation for the patient. Optionally, in the case where the doctor needs to inject a variety of different drugs for the patient, the drug metabolism model corresponding to the drug can be used to obtain the time required for each of them to reach the effective concentration from the start of injection. Since different drugs have different onset times, the doctor can control the order of injection between different drugs, so that the time when multiple drugs take effect is closer, which can better meet the needs of clinical application.

[0106] In some implementations of the present application, the above method further includes:

[0107] According to the first configuration parameter and the drug metabolism model, the relationship between the concentration of the drug and time in the target area is calculated from the start of the drug injection, and the relationship is displayed on a display.

[0108] In this embodiment, the relationship between the concentration of the drug in the target area and time can be obtained, and the relationship is displayed on the display, which can assist doctors in observing the appropriate time to establish an artificial airway.

[0109] In some implementations of the present application, the above method further includes:

[0110] receiving configuration parameter change information of the above-mentioned drug;

[0111] According to the configuration parameter change information, modify the first configuration parameter to obtain the second configuration parameter, wherein the second configuration parameter includes a second target concentration;

[0112] The time required for the concentration of the drug to reach the second target concentration in the target area is calculated according to the second configuration parameter and the drug metabolism model to obtain a second time.

[0113] In the process of injecting the above-mentioned drug into the patient, the patient may have some abnormal conditions due to personal reasons. For example, the patient's blood pressure, heart rate and breathing may change significantly. In this case, the configuration parameters of the above-mentioned drug need to be changed to alleviate the abnormal conditions of the above-mentioned patient. The modified second configuration parameters are obtained. According to the second configuration parameters and the drug metabolism model, the time required for the concentration of the above-mentioned drug to reach the second target concentration, that is, the second time, can be recalculated. This embodiment can be applied to the scenario where the patient's body is abnormal, and timely adjustments can be made to improve the success rate of establishing an artificial airway.

[0114] In some implementations of the present application, before receiving the configuration parameter change information of the drug, the method further includes:

[0115] Acquiring status change information of the patient, where the status change information is used to indicate a sudden change in the patient's physical status;

[0116] The configuration parameter change information is determined based on the status change information.

[0117] In this embodiment, the configuration parameter information is changed according to the sudden situation of the patient's physical condition, and it is determined how to change the configuration parameter information of the drug. This can be applied to the scenario where the patient's body is abnormal, and timely adjustments can be made to improve the success rate of establishing an artificial airway.

[0118] In an embodiment of the present application, a corresponding drug metabolism model can be obtained based on the above-mentioned drug. According to the configuration parameters corresponding to the above-mentioned drug and the drug metabolism model, the time required for the drug concentration in the above-mentioned target area to reach the target concentration can be obtained. The onset time of the drug can be predicted more accurately. At this onset time, the patient's body will be in a state suitable for establishing an artificial airway, and the appropriate time to establish an artificial airway for the patient can be objectively determined, thereby improving the success rate of establishing an artificial airway.

[0119] The following is an introduction to the auxiliary establishment method of an artificial airway provided in the embodiment of the present application in combination with the application scenario of establishing an artificial airway for a patient in clinical practice. Figure 2 As shown, the method comprises the following steps:

[0120] 201. Receive drug selection information, where the drug selection information is used to determine a drug.

[0121] Before establishing an artificial airway, the patient needs to be injected with suitable anesthetic drugs so that the patient's body reaches a state suitable for intubation. For example, the above-mentioned drugs can be propofol, rocuronium bromide, dexmedetomidine and other drugs, which are not limited in this embodiment of the present application.

[0122] 202. Obtain a drug metabolism model corresponding to the above drug.

[0123] After determining the above-mentioned drugs that need to be injected into the patient, a drug metabolism model corresponding to the above-mentioned drugs can be obtained based on the above-mentioned drugs. The drug metabolism model is used to indicate the relationship between the concentration and time of the drug in the target area of ​​the human body when the drug is initially injected into the above-mentioned patient. Different drugs have different target areas of action.

[0124] 203. Obtain a first configuration parameter of the drug, where the first configuration parameter includes a first target concentration.

[0125] The above-mentioned first configuration parameters are configuration parameters that need to be determined before injecting the drug into the above-mentioned patient. Exemplarily, the above-mentioned first configuration parameters include other parameters such as the first ratio concentration, the first infusion rate and the above-mentioned first target concentration. These parameters can be determined based on the status information of the above-mentioned patient. Due to the different statuses of different people, the settings of the configuration parameters of the above-mentioned drug are also different. The above-mentioned first target concentration is a concentration of the above-mentioned drug in the above-mentioned target area that is effective and will not produce toxic reactions.

[0126] 204. Calculate, based on the first configuration parameter and the drug metabolism model, the time required for the concentration of the drug to reach the first target concentration in the target area to obtain a first time.

[0127] In an embodiment of the present application, based on the above-mentioned first configuration parameters and the above-mentioned drug metabolism model, the time required for the concentration of the above-mentioned drug to reach the above-mentioned first target concentration can be obtained. From the injection of the above-mentioned drug, after the above-mentioned first time, the first time is the onset time of the above-mentioned drug. The doctor can establish an artificial airway for the above-mentioned patient at the onset time.

[0128] 205. Calculate the change relationship between the concentration of the drug and time in the target area from the start of the drug injection, and display the change relationship on a display.

[0129] In the embodiment of the present application, in order to more clearly show the relationship between the concentration of the above-mentioned drug and time, the above-mentioned relationship can be displayed on the above-mentioned display. Optionally, the relationship between the concentration of the above-mentioned drug and time in the above-mentioned target area can be displayed in real time, or the relationship between the concentration of the drug and time in the future period of time starting from the injection of the drug can be displayed. The embodiment of the present application does not limit this. For a more detailed description of the relationship, please refer to Figure 3 , Figure 3 A graph showing the relationship between the concentration and time of a drug provided in an embodiment of the present application.

[0130] like Figure 3The method comprises a rectangular coordinate axis and two concentration change curves 301 and 302. The concentration change curves 301 and 302 represent the real-time change relationship between the drug and time. The horizontal axis of the rectangular coordinate axis is the time axis, the vertical axis is the drug concentration axis, the horizontal axis is the time (T), the unit is seconds (s), the vertical axis is the drug concentration (C), the unit is milligrams per milliliter (mg / ml), the concentration change curve 301 intersects with the concentration axis at point C1, and the concentration change curve 302 intersects with the concentration axis at point C2. The concentration change curve 301 represents the concentration of the drug in the plasma. The relationship between concentration and time. The concentration change curve 302 shows the relationship between the concentration and time of the above-mentioned drug in the effect chamber. According to the horizontal axis time axis, the 0 position represents the current time, and the positive and negative semi-axis of the horizontal axis represent the future and past time points, respectively. For example, for the 30 position on the horizontal axis, the time point represented is the 30th second in the future, and for the -60 position on the horizontal axis, the time point represented is the 60th second in the past. Combined with the vertical axis, it can be understood that point C1 and point C2 represent the real-time concentration of the above-mentioned drug in the plasma and in the effect chamber at the current moment, respectively. According to the Figure 3 , the doctor can observe the changes in the concentration of the above-mentioned drugs in real time, and can obtain the time when the concentration of the above-mentioned drugs reaches the preset target concentration.

[0131] For a more detailed description of this change relationship, see Figure 4 , Figure 4 A graph showing the relationship between the concentration and time of another drug provided in the embodiments of the present application.

[0132] like Figure 4 The method comprises a rectangular coordinate axis and two concentration change curves 401 and 402. The concentration change curves 401 and 402 represent the changing relationship between the drug and time. The horizontal axis of the rectangular coordinate axis is the time axis, the vertical axis is the drug concentration axis, the horizontal axis is the time (T), the unit is seconds (s), and the vertical axis is the drug concentration (C), the unit is milligrams per milliliter (mg / ml). The concentration change curve 401 represents the changing relationship between the concentration of the above-mentioned drug in plasma and time, and the concentration change curve 402 represents the changing relationship between the concentration of the above-mentioned drug in the effect chamber and time. According to Figure 4 On the horizontal axis, t0 is the time point when the above-mentioned drug begins to be injected into the body, t1, t2, ... t7 are the time points after t0. Based on the preset target concentration, the doctor can obtain the time when the concentration of the above-mentioned drug in the corresponding target area reaches the above-mentioned target concentration.

[0133] 206. Obtain the patient's status change information.

[0134] The above-mentioned state change information includes other information such as the patient's heart rate changes, blood pressure changes, and body temperature changes. During the injection of the above-mentioned drugs, some patients may experience some symptoms of stress response. In this case, it is necessary to obtain the patient's more prominent state change information.

[0135] 207. Determine configuration parameter change information according to the above state change information.

[0136] According to the above-mentioned state change information of the above-mentioned patient, the doctor can determine how to modify the above-mentioned first configuration parameter to alleviate the patient's stress response.

[0137] 208. Modify the first configuration parameter according to the configuration parameter change information to obtain a second configuration parameter, where the second configuration parameter includes a second target concentration.

[0138] 209. Calculate the time required for the concentration of the drug to reach the second target concentration in the target area according to the second configuration parameter and the drug metabolism model to obtain a second time.

[0139] In an embodiment of the present application, based on the updated configuration parameters and the above-mentioned drug metabolism model, the time required for the concentration of the above-mentioned drug to reach the above-mentioned second target concentration in the above-mentioned target area can be recalculated, which can alleviate the above-mentioned patient's stress response and enable the above-mentioned drug to achieve the expected drug effect.

[0140] The embodiment of the present application selects drugs related to establishing an artificial airway and obtains a corresponding drug metabolism model, configures appropriate drug configuration parameters according to the patient's status information, and obtains the time required for the above-mentioned drugs to reach a preset target concentration through the drug metabolism model. During the injection process, the above-mentioned drug configuration parameters can be reset according to the patient's status changes to obtain the time required for the new concentration of the above-mentioned drugs to reach the preset target concentration. This can be applicable to a variety of application scenarios, take into account individual differences among patients, and improve the success rate of establishing an artificial airway.

[0141] The following describes the process of assisting the establishment of an artificial airway in conjunction with the assisting establishment device of the artificial airway. Figure 5 A schematic diagram of the structure of an auxiliary device for establishing an artificial airway provided in an embodiment of the present application. Figure 5 As shown, the device comprises:

[0142] A receiving unit 501 is used to receive drug selection information, where the drug selection information is used to determine a drug;

[0143] An acquisition unit 503 is used to acquire a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used to indicate the relationship between the concentration and time of the drug in the target area of ​​the human body;

[0144] The acquisition unit 503 is further used to acquire a first configuration parameter of the drug, wherein the first configuration parameter includes a first target concentration;

[0145] The calculation unit 505 is used to calculate the time required for the concentration of the drug to reach the first target concentration in the target area according to the first configuration parameter and the drug metabolism model, so as to obtain a first time.

[0146] In a possible implementation manner of the second aspect, the first configuration parameter further includes a target control method, and the target control method includes plasma target control or effect chamber target control;

[0147] When the target control method is the plasma target control, the target area is the plasma;

[0148] When the above-mentioned target control method is the above-mentioned effect chamber target control, the above-mentioned target area is the effect chamber.

[0149] In a possible implementation manner of the second aspect, the first configuration parameter further includes a target control mode, and the target control mode includes plasma target control and effect chamber target control;

[0150] The target area is the plasma and the effect chamber, and the first target concentration includes a first target plasma concentration and a first target effect chamber concentration;

[0151] The calculation unit 505 is specifically used to calculate the time required for the concentration of the drug in the plasma to reach the first target plasma concentration according to the first configuration parameter and the drug metabolism model, so as to obtain the first time;

[0152] Alternatively, the calculation unit 505 is specifically used to calculate the time required for the concentration of the drug in the effect chamber to reach the first target effect chamber concentration, to obtain the first time;

[0153] Alternatively, the calculation unit 505 is specifically used to calculate the time required for the concentration of the drug in the plasma and the effect chamber to reach the first target plasma concentration and the first target effect chamber concentration to obtain the first time.

[0154] In a possible implementation of the second aspect, the first configuration parameter further includes a first ratio concentration and a first infusion rate;

[0155] The acquisition unit 503 is also used to acquire the patient's status information;

[0156] The above device also includes:

[0157] The determination unit 504 is used to determine the first ratio concentration and the first infusion rate according to the state information.

[0158] In a possible implementation of the second aspect, the calculation unit 505 is further configured to calculate, based on the first configuration parameter and the drug metabolism model, a relationship between the concentration of the drug in the target area and time starting from the start of the drug injection;

[0159] The above device also includes:

[0160] The display unit is used to display the above-mentioned change relationship on a display.

[0161] In a possible implementation of the second aspect, the receiving unit 501 is further configured to receive configuration parameter change information of the drug;

[0162] The calculation unit 505 is used to calculate the time required for the concentration of the drug to reach a second target concentration in the target area according to the second configuration parameter and the drug metabolism model, so as to obtain a second time.

[0163] The above device also includes:

[0164] The modification unit 502 is used to modify the first configuration parameter according to the configuration parameter change information to obtain the second configuration parameter, where the second configuration parameter includes the second target concentration.

[0165] In a possible implementation manner of the second aspect, the acquisition unit 503 is further used to acquire state change information of the patient, where the state change information is used to indicate a sudden change in the physical state of the patient;

[0166] The determination unit 504 is further configured to determine the configuration parameter change information according to the state change information.

[0167] It should be understood that the division of each unit in the above partitioning device is only a division of logical functions. In actual implementation, it can be fully or partially integrated into a physical entity, or it can be physically separated. For example, the above units can be separately established processing elements, or they can be integrated in a chip of the terminal for implementation. In addition, they can also be stored in the storage element of the controller in the form of program code, and called and executed by a processing element of the processor. The functions of the above units. In addition, the units can be integrated together or implemented independently. The processing element here can be an integrated circuit chip with signal processing capabilities. In the implementation process, the steps of the above method or the above units can be completed by hardware integrated logic circuits in the processor element or software instructions. The processing element can be a general processor, such as a central processing unit (CPU), or one or more integrated circuits configured to implement the above method, such as one or more application-specific integrated circuits (ASICs), or one or more microprocessors (DSPs), or one or more field programmable gate arrays (FPGAs).

[0168] Figure 6 This is a schematic diagram of the structure of an electronic device provided in an embodiment of the present application. Figure 6 As shown, the electronic device 600 includes a processor 601, a memory 602 and a communication interface 603; the processor 601, the memory 602 and the communication interface 603 are interconnected via a bus.

[0169] The memory 602 includes, but is not limited to, random access memory (RAM), read-only memory (ROM), erasable programmable read-only memory (EPROM), or portable read-only memory (CDROM), and the memory 602 is used for related instructions and data. The communication interface 603 is used to receive and send data, which can be implemented Figure 5 The functions of the receiving unit 501 and the acquiring unit 503 are shown in FIG.

[0170] The processor 601 may be one or more central processing units (CPUs). In the case where the processor 601 is a CPU, the CPU may be a single-core CPU or a multi-core CPU. Specifically, the processor 601 may implement Figure 5 The functions of the modification unit 502, the determination unit 504 and the calculation unit 505 are modified.

[0171] The processor 601 in the electronic device 600 is used to read the program code stored in the memory 602 to execute the auxiliary method for establishing an artificial airway in the aforementioned embodiment.

[0172] In an embodiment of the present application, a computer-readable storage medium is provided, and the computer-readable storage medium stores a computer program. When the computer program is executed by a processor, the following is achieved: receiving drug selection information, the drug selection information is used to determine the drug, obtaining a drug metabolism model corresponding to the drug, the drug metabolism model is used to indicate the relationship between the concentration and time of the drug in a target area of ​​the human body, obtaining a first configuration parameter of the drug, the first configuration parameter includes a first target concentration, and according to the first configuration parameter and the drug metabolism model, calculating the time required for the concentration of the drug to reach the first target concentration in the target area to obtain the first time.

[0173] Those skilled in the art will appreciate that embodiments of the present invention may be provided as methods, systems, or computer program products. Therefore, the present invention may take the form of a complete hardware embodiment, a complete software embodiment, or an embodiment combining software and hardware. Moreover, the present invention may take the form of a computer program product implemented on one or more computer-usable storage media (including but not limited to disk storage, CD-ROM, optical storage, etc.) containing computer-usable program code.

[0174] The present invention is described by flowcharts and / or block diagrams of methods, devices (systems), and computer program products according to embodiments of the present invention. It should be understood that each process and / or block in the flowchart and / or block diagram, as well as the combination of processes and / or blocks in the flowchart and / or block diagram, can be implemented by computer program instructions. These computer program instructions can be provided to a processor of a general-purpose computer, a special-purpose computer, an embedded processor, or other programmable data processing device to generate a machine, so that the instructions executed by the processor of the computer or other programmable data processing device generate instructions for implementing the processes in the flowchart and / or block diagram. Figure 1 A process or multiple processes and / or boxes Figure 1 A device that provides the functions specified in a block or multiple blocks.

[0175] These computer program instructions may also be stored in a computer-readable memory capable of directing a computer or other programmable data processing device to operate in a specific manner, so that the instructions stored in the computer-readable memory produce an article of manufacture comprising an instruction device, which implements the process Figure 1 A process or multiple processes and / or boxes Figure 1 A function specified in one or more boxes.

[0176] These computer program instructions can also be loaded onto a computer or other programmable data processing device so that a series of operating steps are executed on the computer or other programmable device to produce a computer-implemented process, thereby providing instructions for implementing the process. Figure 1 A process or multiple processes and / or boxes Figure 1 The steps for the functions specified in one or more boxes.

Claims

1. A method for assisting the establishment of an artificial airway, characterized in that: The method comprises: receiving drug selection information, wherein the drug selection information is used to determine a drug; Acquiring a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used to indicate the relationship between the concentration and time of the drug in a target area of ​​a human body; Obtain patient status information; Determining a first ratio concentration and a first infusion rate according to the state information; Acquire first configuration parameters of the drug, where the first configuration parameters include a first target concentration, the first ratio concentration, and the first infusion rate; According to the first configuration parameter and the drug metabolism model, calculating the time required for the concentration of the drug to reach the first target concentration in the target area, and obtaining a first time, wherein the first time is used to represent the time for establishing an artificial airway after the drug is injected into a human body; According to the first configuration parameter and the drug metabolism model, the relationship between the concentration of the drug and time in the target area is calculated from the start of the drug injection, and the relationship is displayed on a display.

2. The method according to claim 1, characterized in that The first configuration parameter also includes a target control method, and the target control method includes plasma target control or effect chamber target control; When the target control method is the plasma target control, the target area is plasma; When the target control method is the effect chamber target control, the target area is the effect chamber.

3. The method according to claim 1, characterized in that The first configuration parameter also includes a target control method, and the target control method includes plasma target control and effect chamber target control; The target areas are the plasma and the effect chamber, and the first target concentration includes a first target plasma concentration and a first target effect chamber concentration; The step of calculating, according to the first configuration parameter and the drug metabolism model, the time required for the concentration of the drug to reach the first target concentration in the target area to obtain the first time comprises: Calculating, according to the first configuration parameter and the drug metabolism model, the time required for the concentration of the drug in the plasma to reach the first target plasma concentration, to obtain the first time; Alternatively, the time required for the concentration of the drug in the effect chamber to reach the first target effect chamber concentration is calculated to obtain the first time; Alternatively, the time required for the concentration of the drug in the plasma and the effect chamber to reach the first target plasma concentration and the first target effect chamber concentration is calculated to obtain the first time.

4. The method according to claim 1, characterized in that The method further comprises: receiving configuration parameter change information of the drug; Modify the first configuration parameter according to the configuration parameter change information to obtain a second configuration parameter, wherein the second configuration parameter includes a second target concentration; The time required for the concentration of the drug to reach the second target concentration in the target area is calculated according to the second configuration parameter and the drug metabolism model to obtain a second time.

5. The method according to claim 4, before receiving the configuration parameter change information of the drug, the method further comprises: Acquiring state change information of the patient, wherein the state change information is used to indicate a sudden change in the patient's physical state; The configuration parameter change information is determined according to the state change information.

6. An artificial airway auxiliary establishment device, characterized in that: The device comprises: A receiving unit, configured to receive drug selection information, wherein the drug selection information is used to determine a drug; An acquisition unit, used for acquiring a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used for indicating a relationship between a concentration of the drug and time in a target area of ​​a human body; The acquisition unit is further used to acquire the patient's status information; A determination unit, configured to determine a first ratio concentration and a first infusion rate according to the state information; The acquisition unit is further used to acquire first configuration parameters of the drug, wherein the first configuration parameters include a first target concentration, the first ratio concentration, and the first infusion rate; a calculation unit, configured to calculate, according to the first configuration parameter and the drug metabolism model, the time required for the concentration of the drug to reach the first target concentration in the target area, and obtain a first time, wherein the first time is used to represent the time for establishing an artificial airway after the drug is injected into a human body; The calculation unit is further used to calculate the relationship between the concentration of the drug in the target area and time from the start of the drug injection according to the first configuration parameter and the drug metabolism model; A display unit is used to display the change relationship on a display.

7. An electronic device, characterized in that: include: Memory, used to store programs; A processor, configured to execute the program stored in the memory; when the program is executed, the processor is configured to execute the method according to any one of claims 1 to 5.

8. A computer-readable storage medium, characterized in that: The computer storage medium stores a computer program, wherein the computer program includes program instructions, and when the program instructions are executed by a processor, the processor is caused to perform the method according to any one of claims 1 to 5.

Images